Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186118 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
A Phase 1 study of CD 19+ Acute Leukemia, sponsored by Seattle Children's Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03186118 is a Phase 1 study of CD 19+ Acute Leukemia that is active but no longer recruiting, run by Seattle Children's Hospital. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03186118, a Phase 1 study of CD 19+ Acute Leukemia, is active but no longer recruiting, sponsored by Seattle Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.
Conditions Studied
Interventions
- BIOLOGICAL T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Study Locations (1)
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-08-04 |
| Est. Completion | 2033-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03186118
The ClinicalTrials.gov registry entry for NCT03186118 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CD 19+ Acute Leukemia appearing as the primary indexed condition, and to 1 intervention - of which T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC) is the first listed.
NCT03186118 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03186118 about?
NCT03186118 is a clinical study titled "Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia". Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following...
What is the current status of trial NCT03186118?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-08-04. Estimated completion is 2033-07.
What conditions does trial NCT03186118 study?
This clinical trial studies the following conditions: CD 19+ Acute Leukemia.
What interventions are being tested in trial NCT03186118?
The interventions under investigation include: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03186118?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03186118 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.